STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
RARE ULTRAGENYX PHARMACEUTICAL INCORPORATED StockScouter® Report
4
StockScouter® Score
ULTRAGENYX PHARMACEUTICAL INCORPORATED, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with slightly less than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- One or more less experienced analysts has modestly increased quarterly earnings estimates for RARE. Positive/Neutral
- Moving average analysis for RARE suggests upward price movement over the medium term. Positive
Concerns
- The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
- Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
B
D
F
D